The technology fills a present gap in diagnostic testing and could contribute to extending the four walls of the health system for COVID-19 and beyond

The startup will develop and commercialize cost-effective, highly sensitive and specific point-of-care diagnostics, applying a novel electrochemical sensor platform created at the Wyss Institute

Low-cost, multiplexed, electrochemical biomarker detection platform will be commercialized in point-of-care diagnostics

Two technologies function at different points of the diagnostic process and could help detect the SARS-CoV-2 virus in the anticipated second wave of the pandemic